[Ip-health] ITPC RE: Good thing or bad thing? [2 Attachments]

Alma De leon almadeleon9 at gmail.com
Tue Oct 2 14:59:54 PDT 2012


David.  Thank you for share this information.

Hugs,


Alma de León

2012/8/20 David Barr <david at thefremontcenter.org>

> Hi -
>
> Pangaea Global AIDS Foundation organized a meeting with advocates on the
> future of generic drug production at the IAC.  Attached are notes from the
> meeting and the presentation provided by CHAI.
>
> David
>
>
>
>
>  David Barr
> david at thefremontcenter.org
> 607-498-5330
>
>
>
> On Aug 20, 2012, at 6:00 AM, Giten Khwairakpam <
> giten.khwairakpam at treatasia.org> wrote:
>
>
>
> Hi all, I was looking forward to some responses in this question. ****
>
> ** **
>
> The trend seems to be deals, higher stakes or buy outs of Indian generic
> firms.****
>
> ****
>
> I am sure this must be having some implications and could potentially
> impact access to medicines (either positively or negatively). ****
>
> ** **
>
> Any insights will be much appreciated.****
>
> ** **
>
> Thanks****
>
> Giten****
>
> ** **
>
> -----Original Message-----
> From: ip-health-bounces at lists.keionline.org [mailto:ip-
> health-bounces at lists.keionline.org] On Behalf Of George Carter
> Sent: Tuesday, August 07, 2012 8:09 PM
> To: Ip-health
> Subject: [Ip-health] Good thing or bad thing?
>
> ** **
>
> Thoughts?****
>
> ** **
>
> NATAP http://natap.org/****
>
> _______________________________________________****
>
> ** **
>
> Mylan launches 18 HIV drugs in India****
>
> ** **
>
> pharmatimes, World News | August 07, 2012 ****
>
> ** **
>
> ** **
>
> Days after linking up with Gilead Sciences to make cheap HIV generics,
> Mylan has started commercial operations in India with the launch of 18
> antiretrovirals for the treatment of the disease.****
>
> ** **
>
> The US generics major notes that India is home to the world's third
> largest population of people with HIV/AIDS, with 2.4 million people living
> with the disease, of which fewer than 20% have access to treatment. Mylan
> says it will have one of the largest field forces exclusively specialising
> in HIV/AIDS in India.****
>
> ** **
>
> Mylan chief executive Heather Bresch said the firm "can set a new standard
> in the treatment of HIV/AIDS in India by providing healthcare providers and
> those living with the disease access to high quality, affordable medicines
> and by supporting physicians in their efforts to educate and treat their
> patients". She added that "we see significant growth potential in India,
> the world's second largest pharmaceutical market by volume, and look
> forward to continuing to expand our operations in India in additional
> therapeutic categories".****
>
> ** **
>
> In August 2006. Mylan spent about $736 million for an up-to-71.5% stake in
> Indian drugmaker Matrix Laboratories and went on to fully acquire the
> Hyderabad-based group. Last week, Mylan and Indian drugmakers Ranbaxy
> Laboratories and Strides Arcolab signed a deal with Gilead Sciences to
> promote access to "high-quality, low-cost generic versions" of the US
> firm's HIV drug Emtriva (emtricitabine) in developing countries.****
>
> ** **
>
> ----------------------------****
>
> Gilead signs low-cost HIV drug pact with India generic firms****
>
> ** **
>
> World News | August 03, 2012****
>
> ** **
>
> ** **
>
> ** **
>
> ** **
>
> Gilead Sciences has linked up with Ranbaxy Laboratories, Mylan and Strides
> Arcolab to promote access to "high-quality, low-cost generic versions" of
> the USA firm's HIV drug Emtriva in developing countries.****
>
> ** **
>
> The deal covers single tablet regimens containing Emtriva (emtricitabine),
> and fixed-dose combinations of the drug co-formulated with other Gilead HIV
> medicines. The company will provide a technology transfer for the
> manufacture of emtricitabine, "together with funding to assist with
> investment in process improvements to reduce manufacturing costs".****
>
> ** **
>
> Gilead noted that World Health Organisation guidelines recommend
> emtricitabine, as well as the company's Viread (tenofovir disoproxil) as
> preferred components of first- and second-line HIV therapy. However, it
> said that "cost is currently a barrier to broadening access to regimens
> that include emtricitabine when compared to other regimens, including
> widely-used lamivudine (3TC)-based regimens".****
>
> ** **
>
> The new agreements are designed to enable Ranbaxy, Mylan and Strides to
> produce high volumes of FTC/Viread-based therapies, "thereby establishing
> sustainable price parity to these alternative regimens," Gilead said.
> Ranbaxy chief executive Arun Sawhney noted that his firm and Gilead "have a
> strong collaboration going in the area of HIV/AIDS [and] we are pleased to
> extend this association".****
>
> ** **
>
> His counterpart at Gilead, John Martin, said that more than 2.7 million
> patients living with HIV in developing countries are currently receiving a
> Viread-containing regimen, including  Truvada (emtricitabine and tenofovir
> disoproxil). He added that "India’s pharmaceutical industry is a world
> leader in process chemistry, and our ongoing collaboration will be critical
> for furthering access to affordable, high-quality, first-line HIV treatment
> for developing countries".****
>
> ** **
>
> ** **
>
> ** **
>
> _______________________________________________****
>
> NATAP HIV mailing list -- HIV at natap.org****
>
> ** **
>
> This is an annoucement-only mailing list.  Do not reply.****
>
> ** **
>
> To unsubscribe: send a blank email to hiv-request at natap.org with a
> subject of unsubscribe.****
>
> ** **
>
> ** **
>
> For more information, see http://seven.pairlist.net/mailman/listinfo/hiv**
> **
>
> ** **
>
> _______________________________________________****
>
> ** **
>
> _______________________________________________****
>
> Ip-health mailing list****
>
> Ip-health at lists.keionline.org****
>
> http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org*
> ***
>
>
>
>



More information about the Ip-health mailing list